financetom
Business
financetom
/
Business
/
Fiera Capital Q3 Net Earnings Fall; Company Declares Dividend
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Fiera Capital Q3 Net Earnings Fall; Company Declares Dividend
Nov 13, 2025 8:18 AM

10:48 AM EST, 11/13/2025 (MT Newswires) -- Fiera Capital ( FRRPF ) , an independent asset-management firm, on Thursday reported a fall in net earnings in the third quarter due to lower revenues and higher restructuring costs.

For the three-months ended Sept. 30, net earnings was $5.8 million compared with $12.6 million, a year earlier. Adjusted net earnings per share for the quarter was $0.23 compared with $0.25 per share, a year-ago, but beat consensus estimate compiled by FactSet of $0.22 per share.

Revenue for the quarter decreased to $167.1 million compared with $171.7 million a year-ago, primarily due to lower base management fees in Public Markets and lower other revenues, partly offset by higher base management fees in Private Markets. The results missed consensus estimate compiled by FactSet of $166.9 million.

"This quarter we delivered positive net organic growth of close to $900 million, returning the firm to positive total net flows" said Fiera Capital ( FRRPF ) Chief Executive Maxime Menard.

The board also declared a quarterly dividend of $0.108 per Class A Share and Class B Share, unchanged from the prior quarter, payable on December 22, to shareholders of record at the close of business on November 24.

Shares of the company were last seen up 2.7% at $6.44 on the Toronto Stock Exchange.

Price: 6.48, Change: +0.21, Percent Change: +3.35

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Rexford Industrial Realty Insider Sold Shares Worth $1,483,343, According to a Recent SEC Filing
Rexford Industrial Realty Insider Sold Shares Worth $1,483,343, According to a Recent SEC Filing
Jul 29, 2024
03:56 AM EDT, 07/29/2024 (MT Newswires) -- Howard Schwimmer, Director, Co-Chief Executive Officer, Co-President, on July 24, 2024, sold 30,358 shares in Rexford Industrial Realty ( REXR ) for $1,483,343. Following the Form 4 filing with the SEC, Schwimmer has control over a total of 64,248 shares of the company, with 50,673 shares held directly and 13,575 controlled indirectly. SEC...
Moderna Insider Sold Shares Worth $1,766,972, According to a Recent SEC Filing
Moderna Insider Sold Shares Worth $1,766,972, According to a Recent SEC Filing
Jul 29, 2024
03:56 AM EDT, 07/29/2024 (MT Newswires) -- Noubar Afeyan, Director, on July 24, 2024, sold 15,000 shares in Moderna ( MRNA ) for $1,766,972. Following the Form 4 filing with the SEC, Afeyan has control over a total of 6,871,164 shares of the company, with 2,239,015 shares held directly and 4,632,149 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1682852/000095017024087026/xslF345X03/ownership.xml Price: 121.39, Change: -0.72,...
Argan Insider Sold Shares Worth $1,177,274, According to a Recent SEC Filing
Argan Insider Sold Shares Worth $1,177,274, According to a Recent SEC Filing
Jul 29, 2024
03:54 AM EDT, 07/29/2024 (MT Newswires) -- David Hibbert Watson, Director, President and Chief Executive Officer, on July 24, 2024, sold 15,134 shares in Argan (AGX) for $1,177,274. Following the Form 4 filing with the SEC, Watson has control over a total of 44,348 shares of the company, with 44,348 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/100591/000141588924020157/xslF345X03/form4-07262024_040704.xml Price: 78.79, Change: +1.20,...
GSK settles another heartburn drug lawsuit in Illinois
GSK settles another heartburn drug lawsuit in Illinois
Jul 29, 2024
July 29 (Reuters) - British drugmaker GSK said on Monday it has agreed to confidentially settle a lawsuit in Illinois that alleged its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements to end costly litigation. First approved in 1983, Zantac, sold at different times by GSK, Pfizer ( PFE ) , Sanofi and Boehringer Ingelheim,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved